| Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos (t) ide therapy M Bazinet, V Pântea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Gastroenterology 158 (8), 2180-2194, 2020 | 219 | 2020 |
| Safety and efficacy of bulevirtide monotherapy and in combination with peginterferon alfa-2a in patients with chronic hepatitis delta: 24 weeks interim data of MYR204 phase 2b … T Asselah, SS Arama, P Bogomolov, M Bourliere, H Fontaine, GS Gherlan, ... Journal of Hepatology, Supplement 75 (S2), 291-291, 2021 | 54 | 2021 |
| Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Journal of Hepatology 66 (1), S256-S257, 2017 | 35 | 2017 |
| Analysis of HBsAg Immunocomplexes and cccDNA activity during and persisting after NAP‐based therapy M Bazinet, M Anderson, V Pântea, G Placinta, I Moscalu, V Cebotarescu, ... Hepatology Communications 5 (11), 1873-1887, 2021 | 13 | 2021 |
| Benefit of transaminase elevations in establishing functional cure of HBV infection during NAP‐based combination therapy M Bazinet, V Pântea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Journal of Viral Hepatitis 28 (5), 817-825, 2021 | 13 | 2021 |
| Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: ongoing follow-up results from the REP 401 study M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Age (average/median) 36, 36, 2019 | 13 | 2019 |
| Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and … A Vaillant, M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, ... Journal of Hepatology 68, S517, 2018 | 13 | 2018 |
| HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection M Bazinet, M Anderson, V Pântea, G Placinta, I Moscalu, V Cebotarescu, ... Hepatology communications 6 (8), 1870-1880, 2022 | 12 | 2022 |
| Evolution of the toxocariasis monoinvasion in comparison with the toxocariasis associated with other parasites in children P Gheorghe, S Tatiana, T Lidia The Moldovan Medical Journal 61 (1), 36-41, 2018 | 12 | 2018 |
| Safety and efficacy of vidofludimus calcium in patients hospitalized with COVID-19: a double-blind, randomized, placebo-controlled, phase 2 trial MJGT Vehreschild, P Atanasov, K Yurko, C Oancea, G Popov, V Smesnoi, ... Infectious Diseases and Therapy 11 (6), 2159-2176, 2022 | 9 | 2022 |
| Preliminary safety and efficacy of REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha 2a in treatment naïve … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Hepatology 64 (6), 1122A-1123A, 2016 | 9 | 2016 |
| Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and … M Bazinet, M Anderson, V Pantea, G Placinta, I Moscalu, V Cebotarescu, ... Journal of Hepatology 73, S142, 2020 | 8 | 2020 |
| Bulevirtide combined with pegylated interferon for chronic hepatitis D T Asselah, V Chulanov, P Lampertico, HH Wedemeyer, A Streinu-Cercel, ... New England Journal of Medicine, 133-143, 2024 | 7 | 2024 |
| Establishment of high rates of functional control and reversal of fibrosis following treatment of HBeAg negative chronic HBV infection with REP 2139-Mg/REP 2165-Mg, tenofovir … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Hepatology 68, 234A-235A, 2018 | 5 | 2018 |
| Interim follow-up analysis in the REP 401 protocol: Functional control of HBeAg negative chronic HBV infection persists after withdrawal of combined therapy with REP 2139 or … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Hepatology 66 (6), 1269A-1269A, 2017 | 5 | 2017 |
| Efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: primary endpoint results from a phase 2b open … T Asselah, P Lampertico, H Wedemeyer, A Streinu-Cercel, V Pantea, ... The Liver Meeting 2023, 2023 | 3 | 2023 |
| Interaction between SArS-CoV-2 and human organism P Gheorghe, P Victor, C Lilia, C Valentin, P Lidia, C Dan The Moldovan Medical Journal 63 (2), 57-62, 2020 | 3 | 2020 |
| Monoinvasion with toxocara canis in children P Gheorghe The Moldovan Medical Journal 61 (2), 17-20, 2018 | 3 | 2018 |
| Rapid monophasic HBsAg decline during NAP-based therapy predicts functional cure L Hershkovich, L Shekhtman, M Bazinet, V Pantea, G Placinta, I Moscalu, ... Hepatology 74, 514A-515A, 2021 | 2 | 2021 |
| Asigurarea calităţii în diagnosticul microbiologic al infecţiilor tractului urinar: Ghid O Burduniuc, E Ceban, G Bălan, G Plăcintă, A Vişnevschi, O Sofronie, ... ÎS Firma Editorială Poligrafică „Tipografia Centrală”, 2021 | 2 | 2021 |
Victor Panteaprofesor universitar, USMF N.Testemitanu在 usmf.md 的电子邮件经过验证
